U.S. Oncology partners on big genetics venture in TX

U.S. Oncology and Baylor Health Care System are teaming up on an ambitious new joint venture that will explore the development of new, personalized cancer therapies targeted at specific genes. The Dallas Business Journal dug up a rough outline of their plans to hire up to 900 people in Lewisville, TX who will earn an annual payroll of $67 million.

The Business Journal didn't reach any of the principals in the deal, but it says that the company has leased a 172,000-square-foot facility and will have 214 people on staff by the end of this year. The company plans to focus on pharmacogenomics--the interplay between genetics and new drugs. And they're looking for "cytogenetics, medical technologists, laboratory managers, a global logistics manager and a directory of quality assurance and regulatory affairs."

- here's the story from the Dallas Business Journal

Suggested Articles

Insitro picked up $143 million to build out its technology, pursue new targets and advance treatments for genetically defined patient groups.

Generation Bio filed for a $215 million IPO to advance a pair of gene therapies for liver disease and push one of them into the clinic.

The IPO will push Avidity's lead muscle disorder program through IND-enabling studies and into the clinic in 2021.